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works for HTA. This study seeks to systematically review the literature to identify 
existing ethics frameworks for HTA in order to provide an overview of their method-
ological features and to gain a better understanding of the areas of commonality and 
divergence between different frameworks. Methods: We conducted a systematic 
search of literature, without limits of time and language, to identify the guidance 
documents or practical frameworks published up to October 1st 2013. Results: The 
review identified 22 frameworks, varying in their philosophical approach, structure, 
and comprehensiveness. They were designed for different purposes throughout the 
HTA process, ranging from helping HTA producers in identification, appraisal and 
analysis of ethical data to supporting decision-makers in making better informed 
value-sensitive decisions. They frequently promoted analytical methods that com-
bined normative reflection with descriptive approaches to the analysis of values of 
stakeholders and other societal or technical actors. ConClusions: The choice of a 
method for collection and analysis of ethical data seems to depend on the context 
in which technology is being assessed, the purpose of analysis, and availability of 
required resources.
ReseaRch on Methods – statistical Methods
PRM113
coMPaRing PRoPensity scoRe, PRoPensity scoRe with covaRiates 
and genetic algoRithM Methods foR covaRiate Matching in 
obseRvational studies
Claeys C., Bakken D.G., Wasserman D., Spilman J.
KJT Group, Inc., Honeoye Falls, NY, USA
objeCtives: As the population ages an increasing number of individuals are provid-
ing informal (unpaid) care for an aging relative. We compare three different methods 
of covariate matching to determine the effect of caregiving on the mental health 
states of informal caregivers. Covariate matching methods pair observations from 
different treatment groups by matching the members of each pair on a set or vector 
of covariates that would be randomly distributed across the groups in a randomized 
trial. Methods: Multiple waves of an online survey conducted among a representa-
tive sample of U.S. adults yielded 740 informal caregivers and 2260 non-caregivers. 
We applied three different methods for covariate matching to determine the “aver-
age effect of treatment on the treated” (ATT) of caregiving on mental health states 
(MH): 1. Propensity score within calipers; 2. Propensity score and covariates within 
calipers; and 3. Genetic algorithm matching. Results: All three methods provide 
adequate balance on the covariates used for matching. Methods 2 and 3 produce 
the best covariate balance, with absolute mean covariate differences less 0.0008 on 
all covariates and less than 0.00001 on the core set of covariates. Because methods 
that censor observations (i.e. matching within calipers) may artificially improve 
covariate balance, we take the ATT estimate from genetic matching to be the least 
biased estimate of the true effect. Using a standard 5-point self-report measure of 
mental health, caregivers, on average, report a mental health state that is 5.4% worse 
than non-caregivers (roughly one-fourth “less healthy” within any given scale range 
(e.g. 2-3, 3-4). ConClusions: As all three methods provide adequate matching, our 
consideration turns to bias reduction and the fact that the genetic matching does 
not require that we estimate the propensity score prior to matching. We consider 
the drivers or caregiver MH and implications for health care policy.
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aRe industRy funded netwoRk Meta-analyses loweR quality?
Chambers J.D.1, Gunjal S.S.2, Winn A.3, Kennedy I.R.4, Hoey M.G.5, Pyo J.1
1Tufts Medical Center, Boston, MA, USA, 2University of Houston, Houston, TX, USA, 3The 
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objeCtives: To compare the quality and transparency of industry supported network 
meta-analyses with those with non-profit support or no support. Methods: We sys-
tematically searched OVID-Medline for network meta-analyses including at least one 
pharmaceutical. We reviewed each network meta-analysis and evaluated key general 
study characteristics, methodology, and transparency using a checklist of objective 
criteria derived from the ISPOR Taskforce’s recommendations for study conduct and 
reporting. We reported source of study funding when available. When source of fund-
ing was unclear or not reported we contacted the corresponding author. We compared 
the quality and transparency of industry supported network meta-analyses with 
those with non-profit support or no support. Results: Two hundred and fourteen 
studies met our inclusion criteria and were included in our dataset. Source of fund-
ing was identified for 211 studies (98.6%). Industry supported studies tended to be 
published in lower quality medical journals (p< 0.01), and typically included fewer 
studies (p< 0.05) and a smaller total number of patients (p< 0.05). In terms of study 
transparency, industry supported studies less often reported the search terms (p< 0.01) 
and, for analyses conducted using a Bayesian framework, presented the model code 
(p< 0.01). Regarding study methodology, industry supported network meta-analyses 
less often reported a quality assessment of clinical studies included in the network 
meta-analysis (p< 0.01), and less often compared the findings of traditional meta-
analysis and network meta-analysis (p< 0.01). With respect to presentation of findings, 
industry supported studies less often reported the full matrix of head-to-head com-
parisons (p< 0.01), or provided a ranking of treatments (p< 0.01). ConClusions: We 
found that studies with non-profit support or no support funded tended to be more 
transparent and rigorous than industry supported studies. Study findings emphasize 
that users of network meta-analyses should take great care to account for study qual-
ity when interpreting the findings of network meta-analyses.
PRM115
autoMatic develoPMent of clinical PRediction Models with genetic 
PRogRaMMing: a case study in caRdiovasculaR disease
Bannister C.A., Currie C.J., Preece A., Spasic I.
Cardiff University, Cardiff, UK
countries were the following: (1) keep the same date, event, and consequences 
whenever possible (i.e., Tuesday May 4, a 3 alarm fire, destruction of two hotels 
and one restaurant); and (2) substitute the place where the event is located [i.e., 
a city (Cleveland, Ohio)] with a place familiar to the subjects living in the target 
countries. Results: The event (fire) could be kept in all countries. The date had 
to be changed in The Netherlands because it corresponds to a commemoration 
(Remembrance of the Dead) and would have introduced a bias if kept. The verbatim 
“a 3 alarm fire” was impossible to translate literally since no equivalent fire-classifi-
cation system is used in most target countries (except in Canada). It was decided to 
use synonyms of “big” to qualify “fire.” Syntax was also an issue especially in Korea, 
Japan, Romance and Germanic languages where the order of some segments had 
to be inverted. ConClusions: Although simple in its structure, the RBANS story 
memory-test proved to be challenging to translate into 24 languages and required 
a rigorous methodology to preserve the intent of the original.
PRM110
standaRdization of Mental health assessMent – using iteM 
ResPonse theoRy (iRt) to cRoss-calibRate two self-RePoRted Mental 
health tools: the Patient health questionnaiRe (Phq-9) and the sf-
36v2 Mental health (Mh) scale
Bjorner J.B., White M.K., Yarlas A.S.
Optum, Lincoln, RI, USA
objeCtives: Mental health can be measured by numerous instruments, but scores 
are usually not directly comparable. The heterogeneity of scale specific metrics seri-
ously impairs comparability across study results and the communication among 
researchers and clinicians. We aimed to develop and evaluate methods for cross-
calibration of two popular mental health tools: the PHQ-9 and the SF-36v2 MH 
scale. Methods: We analyzed data from the United States and the UK including a 
general population sample (US: 216, UK: 355) and a sample with suspected depres-
sion (US: 169, UK: 153). Multigroup confirmatory bifactor models tested whether 
the two instruments measured the same construct. Differential item function 
(DIF) between general population and depression samples was tested using logis-
tic regression DIF tests. We estimated IRT item parameters using a multigroup 
generalized partial credit model and developed cross-calibration algorithms using 
the summed score cross-calibration approach. The measurement properties of the 
instruments were evaluated by test information functions. Results: In the bifactor 
model, all items loaded strongly on a common factor, supporting that the two scales 
measure the same general mental health construct. We found no indication of DIF, 
supporting that the same item parameters apply to the general population and the 
depression samples. The cross-calibration algorithm revealed a fairly linear relation 
between PHQ-9 score and MH score in the PHQ-9 score range of 10-20 (moderate 
to severe depression), but a non-linear relation at more extreme scores. The PHQ-9 
provided most information for persons with scores in the interval from the general 
population average down to two standard deviations below average, but the MH 
scale provided more information at the lower and upper extremes. ConClusions: 
We successfully developed a procedure for cross-calibrating the PHQ-9 and MH 
scales. These results can be used to compare scores between the two instruments.
PRM111
inteRnal validation of MaPPing analyses foR health technology 
assessMent
Trueman D., Treharne C.
Abacus International, Bicester, UK
objeCtives: Mapping between health status measures is common practice within 
health economic evaluations. The objective of this analysis was to evaluate the suit-
ability of hold-out validation, whereby models are fitted to a subset of data and then 
tested in the remaining observations, compared to other methods of internal valida-
tion utilising full sample approaches in small to medium sized samples. Methods: 
Four models predicting EQ-5D from the SF-12 were estimated using the Medical 
Expenditure Panel Survey. Models were estimated using three hypothetical sample 
sizes of 500, 1,000, and 4,000 observations. For each model and sample size, two 
hold-out validation specifications were compared against alternative estimators of 
error: the naïve resubstitution error; repeated 10-fold cross validation; the optimism-
corrected bootstrap; the 0.632 bootstrap. The results from these estimators were 
compared against asymptotic estimates of the true error indices in the remaining 
observations (n= 15,675). Estimators were evaluated by assessment of bias and vari-
ance. The exercise was repeated 500 times. Results: Hold-out methods were subject 
to the largest variance across all estimators and sample sizes. Variance was lower 
and similar in the full sample estimators (bootstrap and cross-validation methods). 
The extent of bias in any sample size was associated with the degree to which the 
algorithms were adaptive to the training sample data. For the two mapping algorithms 
which were not adaptive to the training sample data, bias was low for all estimators. 
In the two algorithms which were more adaptive to the training sample data, the 
naïve resubstitution error was associated with a downward bias, hold-out methods 
exhibited an upward bias, and all full sample methods exhibited a low degree of 
bias. ConClusions: Hold-out validation exhibited the highest variance of all meth-
ods in all scenarios. Full-sample designs offer lower variance and are preferable to 
continued use of hold-out validation with small to medium sized datasets.
PRM112
a systeMatic Review of Methodological fRaMewoRks foR 
evaluation of ethical consideRations in health technology 
assessMent
Assasi N., Schwartz L., Tarride J.E., Campbell K., Goeree R.
McMaster University, Hamilton, ON, Canada
objeCtives: While advances have been made in development of ethical frame-
works for health technology assessment (HTA), there is no clear agreement on the 
most useful and practical approach to address ethical aspects in HTA. Moreover, 
uncertainty remains about appropriate scope and level of details of ethical frame-
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identify chf and coPd Paitients at high Risk of hosPitalization: 
using PRedictive analytics foR Patient outReach
Wang Q.C., Higgins S.L., Chawla R., Nigam S.
Independence Blue Cross, Philadelphia, PA, USA
objeCtives: To develop predictive models to identify CHF and COPD patients at 
high risk of hospitalization within the next 6 months to be used for case manage-
ment outreach. dAtA souRCes: Data were extracted from several sources and 
included patient diagnoses, service utilization, lab data, and medication adherence 
from a large health insurance claims database, ZIP code level demographic data 
from the U.S. Census, patient level illness burden scores, medical episode group-
ers, Experian consumer and credit information, and call data between patients 
and customer service representatives. study PoPulAtion: All commercial and 
Medicare members who were identified with congestive heart failure (CHF) and 
chronic obstructive pulmonary disease (COPD) and who were continuously enrolled 
for at least 6 months during the model development period and 6 months during 
the predictive period were included. Methods: Using three years of historical 
data from 2010 to 2012 and admissions between January and June 2013 as the target 
variable, the data were randomly split in half as training and validation data. The 
training data were used to build the predictive model. The validation data were used 
to evaluate model performance. Several algorithms were utilized to build predictive 
models: logistic regression, neural networks, and decision trees. The models were 
evaluated based on the lift chart and/or area under the ROC curve. The selected 
models were used to score data and predict future admissions. Results: The key 
factors predicting admissions in the next 6 months included length of time identi-
fied with CHF and COPD, medication adherence, prior admissions, recent specialist 
visits, having had a customer call that mentioned ‘hospital bed/hospital stay’, and 
being on oxygen (for COPD). ConClusions: Four models of predicting patients 
at highest risk of admission have been developed, which were used to generate a 
list of patients with high probability of admission for case management outreach.
PRM119
an analytical Method foR estiMating the boundaRies of an 
incReMental cost-effectiveness Ratio
Kamae I.1, Yamabe K.2, Sugimoto T.1
1The University of Tokyo, Graduate School of Public Policy, Tokyo, Japan, 2MSD.K.K. & HTA and 
Public Policy, Graduate School of Public Policy, The University of Tokyo, Tokyo, Japan
objeCtives: To develop an analytical method which quantifies the reasonable 
limits for any incremental cost-effectiveness ratio (ICER) defined by the slope of a 
line connecting two points on the cost-benefit plane. Methods: Assume that the 
ICER of a target technology vs. its comparator is defined with two points at each of 
which a pair of cost and benefit is given on the C(cost)-E(benefit) plane. In order to 
find a cost-benefit function connecting the two points, an analytical method was 
developed by means of curve-fitting technique with exponential and quadratic mod-
eling. The resultant cost-benefit function was further analytically expanded to the 
derivative, dC/dE, we call it “tangent limit”. Example calculations of the tangent lim-
its were conducted for each model. Results: The analytical development resulted 
in the following equations of the cost-benefit function and the derivative for each 
modeling: C = Exp((E - p)/q) and dC/dE = (1/q) Exp((E - p)/q) for exponential model, 
whilst C = (1/q)E2 - p/q and dC/dE = 2E/q for quadratic model, where p and q are 
parameters determined by costs and benefits of the target technology and its com-
parator. Applying the equations for two hypothetical points, (7.6 QALY, US$100,000) 
and (8.6 QALY, US$150,000), we found that the ICER of 50 bounds with the lower and 
the upper limits, respectively, 40.6 and 60.8 US$(x1000)/QALY for exponential model, 
and as well, 46.9 and 53.1 for quadratic model. Those estimates were not so much 
different as the limits of 43.9 and 65.8 for the ICER of 54.1, obtained by the regression 
analysis presented in the ISPOR New Orleans 2013. ConClusions: Our approach 
can offer a simple and science-based method to estimate boundaries for any ICER. 
It would be useful for negotiations and decisions in value-based pricing in which a 
range of ICER must be considered beyond a single threshold ratio.
PRM120
bias when using PRoPensity scoRe Methods to adjust foR covaRiates 
that aRe not confoundeRs
Chia V.M., Page J.H.
Amgen, Inc, Thousand Oaks, CA, USA
objeCtives: High-dimensional propensity score (PS) methods have been used in 
health care claims data to improve control of confounding by adjusting for a large 
number of covariates that may be proxies for unobserved factors. We have previ-
ously shown that PS models are biased for non-linear link functions when con-
founders were included. We conducted a simulation study to understand whether 
inclusion of covariates that are not confounders may also bias the association by 
estimating Monte Carlo mean bias, relative efficiency (RE) and coverage probability 
(CP) of log odds ratios when covariates only related to the exposure or only related 
to the outcome were included. Methods: We conducted 1000 Monte Carlo simula-
tions, and estimated effect of exposure using logistic regression models. The propen-
sity score was included in the logistic model as a linear predictor or as a smoothed 
covariate using restricted cubic splines. Simulations were conducted for scenarios 
including 5, 15, and 25 covariates. Results: Using the PS with 25 covariates related 
only to the binary exposure, Monte Carlo bias, standard error (SE), RE and CP were 
-0.002, 0.015, 1.34, and 0.94 when the PS was included as a smoothed covariate, and 
–0.002, 0.015, 1.31, and 0.94 when the PS was included as a linear covariate. The 
bias, SE, RE and CP for 25 covariates related to the binary outcome were 0.307, 0.096, 
21.6, and 0 when the PS was included as a linear covariate. Bias tended to increase 
with more covariates. ConClusions: We observed minimal bias when using PS 
models where covariates were related only to the exposure, but substantial bias 
when the covariates were related to the outcome. PS models may not be appropriate 
for logistic models because these models do not adequately deal with errors in the 
outcome due to the covariate.
objeCtives: Genetic programming is an Evolutionary Computing technique, 
inspired by biological evolution, capable of discovering complex non-linear pat-
terns in large datasets. Despite the potential advantages of genetic programming 
over standard statistical methods, its applications to survival analysis are at best 
rare, primarily because of the difficulty in handling censored data. The aim of this 
study was to demonstrate the utility of genetic programming for the automatic 
development of clinical prediction models using cardiovascular disease as a case 
study. Methods: We compared genetic programming and the commonly used 
Cox regression technique in the development of a cardiovascular risk score using 
data from the SMART study, a prospective cohort study designed to identify predic-
tors of future cardiovascular events in patients with symptomatic cardiovascular 
disease. The primary outcome was any cardiovascular event, comprising cardiovas-
cular death and non-fatal stroke and myocardial infarction. The predictive ability 
of the model was assessed in terms of discrimination and calibration. Results: 
3,873 patients were enrolled in the study 1996–2006, aged 19–82 years and with 
460 cardiovascular events. The discrimination of both models was comparable; the 
C-index of the genetic programming model being smaller (0.65; 95% CI: 0.63–0.66) 
but not significantly different from that of the Cox regression model (0.71; 0.67–0.75). 
The calibration of both models was also comparable, indicating similar disagree-
ment between observed and predicted risks. ConClusions: Using empirical data, 
we demonstrated that a prediction model developed by the novel technique of 
genetic programming has a comparable predictive ability to that of Cox regression. 
The genetic programming model was more complicated but was developed in an 
automated fashion and did not require the expertise needed for survival analysis. 
Genetic programming seems a promising technique for the automated development 
of clinical prediction models for diagnostic and prognostic purposes.
PRM116
iMPRoved bootstRaP Point and confidence inteRval estiMation of 
the incReMental cost-effectiveness Ratio (iceR)
Skrepnek G.H.1, Sahai A.2
1The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, 2The University of 
The West Indies, St. Augustine, Trinidad and Tobago
objeCtives: To develop and test a novel approach to estimate the ICER via a new 
bootstrap approach based upon the sample coefficient of variance and optimized via 
computational intelligence. Methods: A novel bootstrap ICER estimation approach 
was developed that incorporated the sample coefficient of variance to better capture 
information within cost-effectiveness data. In this derivation, an optimal design 
value parameter was also obtained via computational intelligence. Across illustra-
tive cost and outcome correlation structures and sample sizes, a simulation study 
of 1111 replications with 999 bootstrap resamples each was conducted utilizing 
MatLab R2012b. Comparative results of point estimates versus the existing bootstrap 
method were presented as relative efficiencies, with 95% confidence intervals (CI) 
presented as coverage probability, coverage error, length, left and right bias, and 
relative bias. Results: The proposed ICER yielded less statistical estimation error 
than the typical bootstrap approach across all cases, with the relative efficiency of 
point estimates ranging from +106.03% to +113.35%. An equal or improved coverage 
error for the CI was also consistently achieved, deviating from the population value 
by zero (i.e., perfect coverage) to 0.0200 versus from 0.0060 to 0.0210. Subsequently, 
an improved shortening of the CI length was noted. The relative bias suggested 
slightly more left bias and less right bias across both positive and negative cost and 
outcome correlation structures, reaching a maximum of 0.5238 for the proposed 
ICER versus 0.2222 for the usual bootstrap. ConClusions: This novel method to 
estimate the ICER via the sample coefficient of variation found improvements in 
the relative efficiency of point estimators and in the coverage error and length of 
the 95% CI across all simulated cases. Irrespective of cost and outcome correlation 
structure, the relative bias of this ICER suggested a slight increase in potential left-
sided bias and decrease in right-sided bias versus the usual bootstrap.
PRM117
using MultiPle iMPutation foR Missing values to identify chRonic 
kidney disease stages
Cai Y.1, Jiao X.2
1IMS Health, Plymouth Meeting, PA, USA, 2IMS Health, Plymouthmeeting, PA, USA
objeCtives: Health care researchers often encounter missing values in many data-
sets. Ultimately, a patient record with missing fields can still carry valuable infor-
mation. This extra information becomes more important to keep in oncology and 
other rare disease studies where sample size is typically limited. The purpose of this 
study is to demonstrate that researchers can benefit from using Multiple Imputation 
(MI) approach to tackle missing value problems. Methods: The model data from 
IMS claims (Dx) and retail prescription (Rx) contained year 2011 patient level CKD 
stage indications, longitudinal drug therapies, days of supplies, titration rates, 
Demographic characteristics, payment type, and physician specialties, etc. We built 
multivariate logistic models to identify Chronic Kidney Disease (CDK) patient stages 
using prescription data in order to further evaluate the prevalence, economic burden 
and market opportunities. Under the general assumption of missing at random 
(MAR), we used MI with regression method to impute the missing monotone and 
categorical values before the modeling process. Results: The pooled results from 
5 MI imputed datasets were reported. Compared with the results from deterministic 
missing imputation approach, the MI showed larger standard error and wider 95% 
confidence interval. The wider CI reflected the additional data uncertainty from the 
missing values. CDK stage 4 (11.2%) had smallest proportion and it had lowest hit 
rate in the prediction model. MI approach showed more CDK stage 4 identifications 
than those from deterministic complete case analysis. ConClusions: This study 
demonstrated that MI is capable of reflecting the underline uncertainty associated 
with the data by introducing random errors into the imputation process. MI can 
generate unbiased results and good standard error estimation when using appro-
priately. On the other hand, with the advent of modern computational technology, 
the MI becomes computationally simple and easy to use.
